Last quarter (Q4 2023), Neuphoria Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Neuphoria Therapeutics's net income was $―. See Neuphoria Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jun 24	Jun 23	Jun 22	Jun 21	Jun 20
Total Revenue	$ ―	$ 15.00K	$ ―	$ 263.63K	$ ―	$ 46.66K
Cost of Revenue	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Gross Profit	$ ―	$ 15.00K	$ ―	$ 263.63K	$ ―	$ 46.66K
Operating Expense	$ ―	$ 17.89M	$ ―	$ 23.17M	$ 13.02M	$ 14.91M
Operating Income	$ ―	$ -17.89M	$ ―	$ -22.91M	$ -13.02M	$ -14.86M
Net Non Operating Interest Income Expense	$ ―	$ 220.10K	$ ―	$ 9.87K	$ -1.44M	$ -1.79M
Other Income Expense	$ ―	$ -2.21M	$ ―	$ -2.03M	$ 5.58M	$ 8.45M
Pretax Income	$ ―	$ -15.58M	$ ―	$ -21.95M	$ -8.88M	$ -6.03M
Tax Provision	$ ―	$ -87.32K	$ ―	$ -191.81K	$ -187.43K	$ -207.61K
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ ―	$ -15.50M	$ ―	$ -20.69M	$ -8.70M	$ -7.12M
Basic EPS	$ ―	$ -0.01	$ -0.22	$ ―	$ -2.02	$ -2.05
Diluted EPS	$ ―	$ -0.01	$ -0.22	$ ―	$ -2.02	$ -2.05
Basic Average Shares	$ ―	$ 1.80B	$ 146.87M	$ ―	$ 4.33M	$ 3.48M
Diluted Average Shares	$ ―	$ 1.80B	$ 146.87M	$ ―	$ 4.33M	$ 3.48M
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ 1.27M	$ ―
Total Expenses	$ ―	$ 17.89M	$ ―	$ 23.17M	$ 13.02M	$ ―
Net Income From Continuing And Discontinued Operation	$ ―	$ -15.50M	$ ―	$ -20.69M	$ -8.70M	$ -7.12M
Normalized Income	$ ―	$ -15.67M	$ ―	$ ―	$ -9.74M	$ -5.99M
Interest Expense	$ ―	$ ―	$ ―	$ ―	$ 1.44M	$ 1.77M
EBIT	$ ―	$ -15.59M	$ ―	$ -21.95M	$ -7.44M	$ -4.26M
EBITDA	$ ―	$ -14.92M	$ ―	$ -23.02M	$ -7.44M	$ -2.09M

Currency in USD

Neuphoria Therapeutics Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing